SCHEMBL613730

SCHEMBL613730

CC(O)CCC(=O)OC1CCCC(C)(C(C)C)C1

nearest known ligand 0.36

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
NAAA Q02083 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CYP2C19 P33261 1/20 0.33
GPBAR1 Q8TDU6 3/20 0.33
ALDH1A1 P00352 1/20 0.32
TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL612164 0.86 CYP2C19 (0.38) NAAACYP2C19
SCHEMBL28012006 0.86 CYP2C19 (0.38) NAAACYP2C19
SCHEMBL16457292 0.86 CYP2C19 (0.38) NAAACYP2C19
SCHEMBL18825657 0.85 NAAA (0.37) NAAASMN1; SMN2CYP2C19
SCHEMBL11408977 0.82 CYP2C19 (0.36) NAAASMN1; SMN2CYP2C19
SCHEMBL9153121 0.82 NAAA (0.61) NAAASMN1; SMN2
SCHEMBL1336805 0.81 GPBAR1 (0.32) GPBAR1
SCHEMBL698620 0.81 CYP2C19 (0.35) NAAACYP2C19
SCHEMBL4063062 0.79 EPHX1 (0.32) CYP2C19
SCHEMBL614025 0.79 CYP19A1 (0.33) CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 372 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210212983-A1 ORAL CANNABINOID DELIVERY FORMULATIONS WITH MOUTHFEEL EXPERIENCE ENHANCERS CHICAGO ATLANTIC ADMIN, LLC 2021-07-15 US claimed
EP-1924148-B1 CONFECTIONERY COMPOSITION INCLUDING AN ELASTOMERIC COMPONENT, A COOKED SACCHARIDE COMPONENT, AND A SENSATE INTERCONTINENTAL GREAT BRANDS LLC (US) 2016-07-20 EP claimed
US-20160128944-A1 COATED PARTICLES AND COMPOSITIONS COMPRISING SAME VYOME THERAPEUTICS LIMITED (IN) 2016-05-12 US claimed
US-9320705-B2 Sensation modifying topical composition foam FOAMIX PHARMACEUTICALS LTD. (IL) 2016-04-26 US claimed
US-20120237453-A1 SENSATION MODIFYING TOPICAL COMPOSITION FOAM FOAMIX LTD. (IL) 2012-09-20 US claimed
US-20100129489-A1 SENSATE-PLATED SANDING COMPOSITION AND PRODUCTS MADE THEREFROM INTERCONTINENTAL GREAT BRANDS LLC 2010-05-27 US claimed
CN-101346072-A Compositions for oral or transdermal delivery providing a heating sensation CADBURY ADAMS USA LLC (US) 2009-01-14 CN claimed
US-20080253973-A1 SENSATION MODIFYING TOPICAL COMPOSITION FOAM FOAMIX LTD. (IL) 2008-10-16 US claimed
US-20070148103-A1 Compositions providing a heating sensation for oral or dermal delivery CADBURY ADAMS USA, LLC. 2007-06-28 US claimed
EP-3869971-B1 CENTER-FILLED CONFECTIONERY PRODUCT; COATED PRODUCT; AND METHODS OF MAKING INTERCONTINENTAL GREAT BRANDS LLC (US) 2024-07-10 EP disclosed
EP-4380553-A1 STABILISED COMPOSITIONS Rumin8 Pty Ltd (AU) 2024-06-12 EP disclosed
CN-117979961-A Stabilized compositions 鲁米兰特私人有限公司 2024-05-03 CN disclosed
US-11930830-B2 System and method of forming multilayer confectionery INTERCONTINENTAL GREAT BRANDS LLC (US) 2024-03-19 US disclosed
US-11896028-B2 Dual-textured confectionery; and methods of making the same INTERCONTINENTAL GREAT BRANDS LLC (US) 2024-02-13 US disclosed
US-20060280834-A1 Center-filled chewing gum composition CADBURY ADAMS USA, LLC. 2006-12-14 US disclosed
US-20060280837-A1 Multi-modality sensations in chewing gum compositions CADBURY ADAMS USA LLC. 2006-12-14 US disclosed
US-20060280836-A1 Multi-modality tastes in chewing gum compositions CADBURY ADAMS USA LLC. 2006-12-14 US disclosed
US-20060280835-A1 Multi-modality flavored chewing gum compositions CADBURY ADAMS USA LLC. 2006-12-14 US disclosed
US-20060263476-A1 Center-filled chewing gum with barrier layer CADBURY ADAMS USA, LLC. 2006-11-23 US disclosed
US-20060263475-A1 Center-filled chewing gum composition CADBURY ADAMS USA, LLC. 2006-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070148103-A1 Compositions providing a heating sensation for oral or dermal delivery TAS2R8, TAS2R60, TAS2R20 NAAA 1248/4885SMN1; SMN2 1011/4885CYP2C19 1261/4885
US-20080253973-A1 SENSATION MODIFYING TOPICAL COMPOSITION FOAM TRPA1, GPR35, TRPV1 NAAA 1587/4885SMN1; SMN2 1331/4885CYP2C19 1460/4885
US-20120237453-A1 SENSATION MODIFYING TOPICAL COMPOSITION FOAM TRPA1, GPR35, TRPV1 NAAA 1587/4885SMN1; SMN2 1331/4885CYP2C19 1460/4885
US-20210212983-A1 ORAL CANNABINOID DELIVERY FORMULATIONS WITH MOUTHFEEL EXPERIENCE ENHANCERS CNR2, CNR1, CPNE4 NAAA 2025/4885SMN1; SMN2 1260/4885CYP2C19 477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.